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Abstract Because it exhibits a remarkable capability to accept
mutational intervention and undergo correct folding and self-
assembly in all viable prokaryotic and eukaryotic expression
systems, hepatitis B core (HBc) protein has been favored over
other proposed particulate carriers. Structurally, the unusual
K-helical organization of HBc dimeric units allows introduction
of foreign peptide sequences into several areas of HBc shells,
including their most protruding spikes. Progress toward full
resolution of the spatial structure as well as accumulation of
chimeric HBc-based structures has brought closer the knowl-
edge-based design of future vaccines, gene therapy tools and
other artificial particulate objects.
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1. Introduction
Supermolecular structures built in a symmetric manner
from hundreds of proteins of one or more types, often called
VLPs (virus-like particles), could serve as molecular carriers,
providing a regular arrangement of wanted polypeptide chains
at the desired positions on the outer surface of the carrier (see
latest review articles [1^4]). Such structures ensure a speci¢c
three-dimensional conformation and a high density of intro-
duced peptides per particle, which are the deciding factors for
their functional activity in inducing immunological response,
binding of receptors, or recognizing low molecular weight
substrates.
The ¢rst models for VLP protein engineering came from
rod-shaped representatives of the Inoviridae (¢lamentous bac-
teriophage f1) and Tobamoviridae (tobacco mosaic virus)
families, as well as from the outer envelopes and the inner
capsids of a representative of the double-stranded DNA virus
family Hepadnaviridae, namely, human hepatitis B virus
(HBV). Whereas phage f1 derivatives initiated a series of rep-
lication-competent viruses employed as particulate carriers,
such as phage-display vectors, and some animal (polio, rhino)
and plant (tobacco mosaic and cowpea mosaic) viruses (see
recent review [4]), HBV nucleocapsid or core protein (HBc)
remains as before the favorite example of non-infectious car-
riers.
As a general advantage, the unusual £exibility and insensi-
tivity to foreign invasions of the HBc molecule are manifested
by its ability to participate in particles of both T = 3 and T = 4
symmetry and therefore to take not only the three A, B, and
C, but also a fourth D conformation in a T = 4 arrangement
[5]. HBc particles possess not only an outstanding ability to
induce B cell, T helper (Th) and cytotoxic T cell (CTL) re-
sponse, but also permit the inserted polypeptides to exhibit
the appropriate immunological properties. HBc molecules re-
tain their ability to form particles and high-level yields in
practically all popular homologous and heterologous expres-
sion systems. Chimeric HBc derivatives are easy to purify
because of their particulate nature, and they can be subjected
to dissociation with subsequent re-association, thereby allow-
ing removal of internal impurities. HBc chimeras are able to
pack nucleic acids, for possible use in gene therapy experi-
ments, or, alternatively, they can be deprived of this ability,
to yield nucleic acid-free preparations.
Here we outline the relationship of functional features of
the HBc shell to its structural peculiarities.
2. Multifunctionality as a major attribute of HBV C
gene-encoded proteins
A portrait of gene C, as it is currently understood, is given
in Fig. 1. Although gene C possess two in-frame initiation
ATG codons, it is accountable for at least four di¡erent poly-
peptides, p25, p22, p21, and p17 [6]. The p21 polypeptide, or
the HBc protein proper and the major constituent of the HBV
nucleocapsid, is synthesized from the second initiation codon.
It participates, besides its structural function, in the full cycle
of viral replication and its regulation, including RNA pack-
aging, DNA synthesis, viral maturation, recognition of viral
envelope proteins and budding from the cell (see [7]). The p25
precore protein is started at the ¢rst ATG codon and becomes
targeted by a signal peptide to a cell secretory pathway where
N-terminal processing will create a p22 species. The latter
undergoes further modi¢cation at the C-terminal region, after
position 149, to generate p17, or e-protein, which is secreted
from the cell as HBe antigen.
The exact role of the precore polypeptides p25 and p22 and
of the HBe antigen in the biology of hepadnaviruses remains
unknown. In the present review, we will restrict the discussion
to the observation that the expression of p22 leads to the
formation of nucleocapsids similar to those made with p21
core protein, and that p21 and p22 may form hybrid nucleo-
capsids [6]. The HBe protein p17 does not form particles, but
enters the secretory pathway and is actively secreted by cells
(see [8]).
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3. Evolutionary history of gene C
Gene C represents the only non-overlapping sequence in the
HBV genome (Fig. 1), although it remains the mostly evolu-
tionarily conserved. The HBV core sequence demonstrates
high similarity (65^67% at the amino acid level) to cores of
rodent: woodchuck (WHV), ground squirrel (GSHV), and
arctic ground squirrel (ASHV) hepadnaviruses, but only
traces of homology with cores of bird: duck (DHBV), and
heron (HHBV) hepadnaviruses (for references see [9]). Re-
cently, the woolly monkey hepatitis B virus (WMHBV), a
probable progenitor of the human viruses, was found [10].
The WMHBV core is practically identical to HBV cores
(85^87% similarity at the amino acid level). HBV, WHV,
and GSHV, but not DHBV core proteins, are able to cross-
oligomerize into mixed particles [11].
Serologically, HBV genomes were classi¢ed into four main
subtypes adw, adr, ayw and ayr, in accordance with the HB
seroreactivity. Structurally, six HBV genotypes A^F were de-
termined [12], and two core genotypes representing the core
sequences of HBV genotype C and most genotype B strains
(core genotype 1) and of HBV genotypes A and D (core
genotype 2) have been described [13]. The mutation clustering
regions for these core genotypes 1 and 2 were located at res-
idues 84^99 and 48^60, respectively [13]. For HBV genotype
F, a mutation clustering region was localized within the amino
acid stretch 57^68 [14]. In total, the sequence 74^101 was
found to be the most ‘hypervariable’ where frequent varia-
tions occur in amino acid residues [15]. Recent investigations
have shown that clustering changes may be directly responsi-
ble for the outcome of the disease, in particular, HBc dele-
tions and missense mutations are related to the development
of liver injury (for example, [16]).
4. Extraordinariness of the spatial structure of HBc molecules
4.1. Direct structural investigations
Early structural investigation of HBV core particles was
undertaken in the mid-1970s when the ¢rst data on their
shape, size, and polypeptide composition appeared [17]. The
existence of two size classes of HBV cores, with a predomi-
nant larger and a less frequently occurring smaller species, has
been detected with particles from HBV-infected human liver
using either electron microscopy of a negatively stained speci-
men [18] or gel ¢ltration [19]. Nevertheless, the ¢rst precise
electron microscopic ultrastructure of native HBV cores ¢xed
for more than 10 years a notion of their composition accord-
ing to T = 3 icosahedral symmetry, built up by 180 subunits
[20]. Since HBV failed to be reproduced in cell cultures, fur-
ther developments in the understanding of HBc structure re-
quired heterologous sources of authentic HBc particles.
Expression of the HBV C gene, not only in various eukary-
otic systems: yeast Saccharomyces cerevisiae, insect Spodop-
tera, frog Xenopus oocytes, mammalian cell cultures, vaccinia
virus (for references see [2,4]), and, recently, in plant Nicotiana
tabacum [21], but also in bacteria such as Escherichia coli,
Bacillus subtilis, Salmonella and Acetobacter [2,4], demon-
strated high-level production of the HBc protein. Over-ex-
pressed HBc protein showed correct self-assembly into natu-
rally shaped particles, in the absence of any other viral
components. Direct electron microscopy comparison of HBc
particles isolated from virions and infected hepatocytes and
the particles from E. coli [18] and from yeast [22] con¢rmed
their ultrastructural superimposability. The size heterogeneity
of bacterial [18,19] and yeast [22] HBc particles suggested the
ability of these expression systems to employ homologous or
similar machinery for synthesis, translocation and folding of
HBc protein as the human cell.
Of particular value in understanding the structure of HBc
particles was the clear demonstration of the dispensability of
the C-terminal protamine-like arginine-rich domain 150^183
of HBc polypeptide both for their ability to form particles,
and, more or less, for the size and morphology of capsids
[23,24]. These HBcv particles are practically indistinguishable
from full-length HBc particles using high resolution electron
cryomicroscopy [5]. In contrast to the full-length HBc par-
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Fig. 1. Portrait of HBV gene C. Structural and functional peculiar-
ities of the HBc molecule are compiled from the publications cited
in the text. The 185-aa length of some HBc representatives belong-
ing to the subtype adw is caused by a 2-aa insertion after position
152. For gene C overlap with genes X and P, the corresponding
amino acid residues of the HBc molecule are indicated. The pre-
dicted N-terminal K-helix of 10 amino acid residues [28] is marked
by a dashed line.
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ticles, they are less stable, and usually appear as empty shells,
[23^26]. Moreover, the ¢rst attempts to apply NMR for anal-
ysis of HBc particles revealed an unusual mobility of the C-
terminal protamine-like domain [27]. Such HBcv particles
play an important role in structural modeling and seem to
be good prospects for further applications such as vaccine
or gene therapy carriers.
The ¢ne 3D organization of HBc particles (Fig. 2) was
revealed at last by electron cryomicroscopy and image proc-
essing [5], and was found to be largely K-helical and quite
unlike previously solved viral capsid proteins [28]. It turned
out that HBc molecules are able to assemble into two particle
sizes, large and small, which corresponded to triangulation
number T = 4 and T = 3 dimer clustered packings, containing
240 and 180 HBc molecules, respectively [5]. Particles are
approximately 34 nm and 30 nm in diameter and show 120
or 90 protruding spikes. The local packing of subunits was
very similar in the two sizes of particle and showed character-
istic spikes and holes on the shell surface. The arrangement of
these spikes and holes led to the proposal that the putative
basic subunit of HBc particle is a dimer having a hammer
head shape, with the protruding spike forming the ‘handle’
and the ‘head’ formed by wedges of the shell domain extend-
ing towards the centers of the rings of 6 or 5 dimers. Full-
length HBc particles contained additional material, probably
RNA, which appeared as a partially icosahedrally ordered
inner shell in the 3D map [5].
At a resolution accuracy of 7.4 Aî , the 3D map revealed the
complete fold of the HBc polypeptide dimer, which consisted
of radial bundles of four long K-helices with the central posi-
tions 78^82 of the major immunodominant region, or MIR
(Fig. 1), of the HBc protein at the tip of the spike [28]. Each
HBc monomer participates in this bundle by an antiparallel K-
helical hairpin about 42 Aî in length, with the straight K-helix
51^78 bounded by conserved proline residues P50 and P79,
and with the kinked K-helix 82^110 ¢nished at glycine G111
(Fig. 1). This K-helix would contain a conserved glycine at
position 94, which might correspond to the position of the
kink, whereas the next, C-terminal K-helix would then corre-
spond to residues 112^128, being terminated by conserved
proline residue P129. A fourth K-helix of the HBc monomer
would lie at the N-terminal part. Most of the monomer-
monomer interface within the dimer consists of interactions
between the two homologous straight K-helices in the two
opposed hairpins [28]. The total length of K-helices corre-
sponds to about 81 aa, which is in good agreement with cir-
cular dichroism measurements [29]. After the tip of the spike,
the next most exposed and accessible feature on the shell sur-
face is region 127^133, a further B cell epitope beyond the
MIR (Fig. 1) lying at the end of the C-terminal K-helix and
making a small protrusion on the surface close to the 5-fold
and 6-fold positions. The accessibility of this region to speci¢c
monoclonal antibodies was con¢rmed by immune competition
[30] and electron microscopy [31] experiments.
An independent cryo-electron microscopy map of the HBc
particle at a resolution of 9 Aî revealed the same protruding
spikes consisting of a 4-helix bundle of the dimeric subunit,
but placed the residues 76^82 on the sides of the spikes [32].
Recently, the location of these residues on the tips of the
spikes was con¢rmed by electron cryomicroscopy of com-
plexes of HBc shells with anti-HBc monoclonal antibodies
recognizing amino acid residues 78^83 [33]. Electron cryomi-
croscopy and 3D image reconstruction were also applied to
compare DHBV and HBV cores of natural and bacterial ori-
gin [31]. In spite of strong di¡erences between duck and hu-
man proteins in both length (262 versus 183 residues) and
amino acid composition, the only signi¢cant structural di¡er-
ences observed are the lobes of density on the lateral edges of
the projecting domain of the HBc dimer. Since the authors
used native HBc isolated from human liver, this study re-con-
¢rmed on an advanced level the faithful reproduction of the
native core structure in bacteria, even in the absence of the
complete viral genome, as well as the idea of evolutionary
variability of the projecting domain.
4.2. Functional complementations to the 3D structure. Role of
speci¢c elements in its maintenance
4.2.1. Dimers and Cys residues. The described HBc fold
[28], although quite di¡erent from the standard L-sheet jelly-
roll packings found in many viral capsids, is consistent with a
large body of functional information about HBV cores. First
of all, it explains the proposed composition of HBc particles
from dimers [34] and the linkage within these dimers by ho-
mologous intermolecular disul¢de bridges, upon aging or ox-
idation, between cysteines C61 [35^37], at the base of hairpin,
and about half-way up the straight K-helix, respectively. Of
four HBc cysteine residues at positions 48, 61, 107 and 183,
the latter constituting the C-terminus, each was replaced in-
dividually, or in all combination, by alanine or serine, and all
were found non-essential for HBc particle formation. How-
ever, cysteine residues stabilize HBc dimers and capsids [37].
Normally, C107 exists as a free thiol buried within the particle
structure, C48 is present partly as a free thiol which is exposed
at the surface of the particle [35]. C61 is always and C48 is
partly involved in interchain disul¢de bonds with the identical
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Fig. 2. Surface-shaded three-dimensional map of the hepatitis B
core shell. The map was computed at 7.4 Aî resolution from electron
micrographs of frozen hydrated specimens and shows a 2-fold view
of the 240-subunit shell. The fold of the core protein, which is
largely K-helical, was deduced from the map (see [28]). The map
was a generous gift of Dr. R.A. Crowther.
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residues of another monomer, leading to dimerization, where-
as C183 is always involved in a disul¢de bond between dimers
generating polymers of S-S-linked dimeric HBc molecules [35^
37]. No intra-chain disul¢de bonds occurred. Interestingly,
WHV core shells have the same pattern of bonding, whereas
the DHBV core lacks any disul¢de bonds, and the single free
thiol, C153, which is equivalent to C107 of HBc, is buried
[35]. Direct HBV replication studies showed, however, that
none of the steps in the viral life cycle from reverse transcrip-
tion to envelopment was principally impaired by replacement
of all cysteines by serine residues, although the stability of the
mutant enveloped particles was lowered in comparison to the
wild type [38].
4.2.2. Cys residues and formation of HBe antigen. During
maturation of the HBe protein (for references see [8]), 19 of
the 29 preC amino acids, as well as about 34 amino acids of
the C-terminal domain are cleaved from the precore p25 pro-
tein (Fig. 1). A 10-aa signal sequence and speci¢cally cysteine
C(37) within it are responsible for the properties which dis-
tinguish the HBe from HBc antigens. The HBc map [28] ex-
plains the block of HBc formation by a possible disul¢de
bond between preC cysteine C(37) and either cysteine C48
or C61, preventing dimerization and therefore shell assembly.
4.2.3. Assembly. C-terminally truncated cores. The interac-
tions between dimers to form the icosahedral shell occur
around the 5-fold and 6-fold axes and are mediated by the
C-terminal helices and tails [28]. This explains why truncation
of the HBc protein before residue 140 inhibits shell assembly
[26], as these contacts could not then be formed, and also why
the C-terminal truncation may in£uence the distribution be-
tween T = 3 and T = 4 shells in bacterially expressed HBc de-
rivatives ([39,40], Borisova and Ose, unpublished observa-
tions).
According to the map [28], HBc protein consists roughly of
an assembly domain 1^149 and a protamine-like (RNA bind-
ing) domain 150^183. Detailed assembly studies in Xenopus
oocytes led to the understanding that nascent HBc polypep-
tides rapidly dimerize, but accumulation of free dimers to a
signature concentration (approximately 0.8 WM) triggers a
highly cooperative capsid assembly reaction, whereas deletion
of a protamine-like domain markedly increases the concentra-
tion of dimers needed to drive capsid assembly [41]. Accord-
ing to recent data [40], the last assembly-competent HBc de-
rivative terminates at position 140, and shows a proportion of
T = 4 isomorphs of approximately 18%. The proportion of
T = 4 capsids increases systematically with shorter deletions
from the C-terminus, and the 142-, 147-, and 149-aa variants
form about 52, 79 and 94% of T = 4 capsids, respectively. The
density map of a HBc mutant with a single gold-labeled cys-
teine at its C-terminal residue 150 supported expecting a bulky
C-terminus to favor formation of the T = 4 capsids [42].
In the study of protease resistance of HBc particles, the
only protease-sensitive region 145^153 was suspected to con-
stitute a hinge between the assembly and protamine-like do-
mains [43]. This region was suggested to form an arm-like
structure, where a single mutation of the proline at position
138, responsible for dimer interactions, to glycine prevented
self-assembly into particles of the full-length HBc protein
dimers, whereas replacement of conserved prolines at posi-
tions 134, 135, and 144 did not a¡ect HBc particle formation
[44].
Two-hybrid and pepscan techniques recently identi¢ed two
strongly interacting regions: 78^117 (region I), which prob-
ably forms part of the dimer interface, and 113 and 143 (re-
gion II) located at the basal tips of the dimer and contributing
to dimer multimerization [45].
4.2.4. N-terminal interactions. There may also be contacts
around the 3-fold axes between N-terminal residues of neigh-
boring dimers [28], which might explain why N-terminal dele-
tions appear to inhibit shell assembly [46]. Although mono-
clonal antibody mapping suggested rather interior location of
the N-terminus of the HBc molecule [47], direct structural
analysis revealed the super¢cial location of 9-aa L-galactosi-
dase amino acid residues added to the N-terminus [48].
5. Mapping of speci¢c functional sites on the HBc molecule
5.1. RNA encapsidation
The location of positions around 140^149 in the map [28] is
consistent with the putative continuation of the protamine-
like tail into the interior of the shell to interact with nucleic
acid. The HBc sequence 1^164 was su⁄cient not only for
RNA binding in a heterologous system [26], but also for spe-
ci¢c HBV pregenome encapsidation and formation of envel-
oped virions [49]. However, cores from the 1^164 variant
failed to support production of relaxed circular HBV DNA,
and further C-terminal residues at least to position 173 were
necessary to restore this ability. Careful analysis attributed
major RNA-recognizing activity to the sequence 150^157,
and DNA-recognizing activity to three repeated SPRRR mo-
tifs within the sequence 157^177 (Fig. 1), although four argi-
nines following the ¢rst 149 amino acid residues also provided
RNA binding [50]. Capsids formed in E. coli by full-length
HBc protein packaged bacterial RNAs in amounts equivalent
to the viral pregenome [42].
5.2. Phosphorylation and nuclear localization
HBc protein appears as a phosphoprotein with the phos-
phorylation of the C-terminal stretch of the molecule [51], on
serine residues within three repeated SPRRR motifs, which
could serve as acceptors of phosphate with equal e⁄ciency
[52] (Fig. 1). Non-phosphorylated HBc protein showed a
higher a⁄nity for nuclear localization than did phosphoryl-
ated protein [52]. Moreover, phosphorylation of the nucleic
acid binding sites in the HBc protein that occurs within the
particles after encapsidation of viral polymerase and prege-
nomic RNA may serve as a signal for viral genome matura-
tion [51].
5.3. Traces of proteolytic domains
One of the most intriguing and unclear features of the HBc
protein remains its relatedness to proteolytic enzymes [53].
However, the direct mutagenic analysis of the highly con-
served HBc sequence 30-LLDTAS-35, similar to the active
site motifs of both aspartic acid and retroviral proteases, sug-
gested strongly that HBc processing to HBe does not depend
on the presence of an intact protease-like sequence [54].
5.4. Immunological epitopes
From the immunological point of view, HBc particles in-
duce the strongest B cell, Th cell and CTL responses, among
other HBV polypeptides, and function as both T-cell-depend-
ent and T-cell-independent antigen (see [1]). Recently, the en-
hanced immunogenicity of HBcAg was explained by its ability
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to be presented by B cells as the primary antigen-presenting
cell in mice [55].
Fig. 1 summarizes existing data on the location of immu-
nological epitopes on the HBc molecule. B cell epitopes are
mapped, ¢rst of all, within the MIR on the tip of the spike,
carrying so-called c and e1 epitopes [56,57]. Only one group
[58] positioned the main B cell epitope to the right of aa 80, at
the region 107^118. The other HBe epitope, e2, was assigned
originally to the region 130^138 [56]. Later, human and mur-
ine anti-HBe antibodies were found to recognize a linear re-
gion around position 130 within the amino acid stretch 126^
135 de¢ned now as the e2 epitope, and the most essential
sequences there are 129-PPA-131 129-PP-Y-132 [59]. Re¢ne-
ment of HBc regions exposed or internalized at the surface of
the particle with monoclonal antibodies led to the ¢nal con-
clusion that sequence 127^133, along with region 78^83, oc-
cupies a super¢cial position on the native HBc shell, whereas
other regions, for example, 133^145 and 9^20, were hidden
[30,60].
In acutely infected hepatitis B patients, the immunodomi-
nant Th epitope 50^69 is recognized irrespective of HLA
background, two further important epitopes are 1^20 and
117^131, and a series of other sequences covering practically
the whole HBc polypeptide were described (see [61]). In mice,
examination of the ¢ne speci¢city of Th cell recognition re-
vealed predominant epitopes speci¢c for each murine strain,
dependent on the H-2 haplotype: 120^140 (haplotype H-2s,b),
100^120 (haplotype H-2f,q), and 85^100 (H-2d mice) [62].
A single HLA-A2-restricted CTL epitope 18^27 has been
identi¢ed in man (see [61]). Additionally, an HBc epitope 141^
151 has been de¢ned by CTL clones from patients with acute
hepatitis B, which is restricted by both HLA-Aw68 and HLA-
A31 molecules. Recent studies allowed the direct isolation of a
naturally processed HBc peptide 88^96 recognized by HLA-
A11-restricted CD8+ CTLs [63]. In mice, the HBc peptides
93^100 [64] and 87^96 [65] were found as CTL epitopes in the
context of Kb binding (H-2b mice) and Kd binding (H-2d
mice), respectively. In macaques, the long-lived CTL response
was directed against a HBc peptide 63^71 [66]. Peptides 84^91
and 88^95 were predicted as good candidates for CTL epito-
pes [15].
6. Capacity of the HBc carrier. Structural and functional fate
of inserted sequences
Long-term empirical search for appropriate targets of pro-
tein engineering manipulations by insertion of various foreign
B cell and T cell epitope sequences (reviewed in [1^4]) pointed
to the MIR region, or the tip of the spike, and to the N- and
C-termini of the HBc molecule, which is in good agreement
with the high-resolution structural data [28]. Summarizing
brie£y all existing data on the insertions of foreign epitopes,
the present conclusions are as follows. Deletions of more than
three amino acid residues are not allowed at the N-terminus
of the HBc molecule. The maximal length of N-terminal in-
sertions reaches 50 amino acids, but the super¢cial accessibil-
ity of insertions is not very high. For C-terminal insertions,
where positions 144, 149, and 156 are used most frequently as
targets, the capacity of vectors exceeds 100 amino acid resi-
dues, and inserted sequences may be exposed, at least partly.
Foreign epitopes inserted at the N- and C-termini are more or
less immunogenic, but chimeras maintain strong intrinsic HBc
antigenicity/immunogenicity.
The situation is much more interesting in the case of foreign
insertions into the MIR of the HBc molecule, which is now
selected as a target of choice and where the region between
two conserved glycines G73 and G94 seems to be dispensable
for HBc self-assembly. It is extremely important that deletions
of proper amino acid residues within this region abrogate the
intrinsic HBc antigenicity/immunogenicity and simultaneously
kake it possible to enhance the immunogenicity of inserted
sequences [67]. Recent investigations also showed the unusu-
ally high capacity, up to 120 amino acids, of the MIR for
foreign insertions [68]. Moreover, strong experimental evi-
dence has been found for the self-assembly competence of
some natural HBc deletion variants (e.g. 86^93 and 77^93)
occurring in patients with progressive liver disease [69].
In general, the HBc carrier ensures a high level of B cell and
T cell immunogenicity to foreign epitopes, especially when
they are inserted into the tips of the spikes. Besides the ability
of the HBc carrier moiety to provide T cell help to inserted
sequences, the HBc shell guarantees the T cell-independent
character of the humoral response against inserted epitopes,
due to the high degree of repetitiveness of the latter and the
proper spacing between them [70]. By using HBc carriers, not
only neutralizing antibodies and speci¢c CTL responses, but
also protection of experimental animals against challenge with
the pathogens were demonstrated (see [4]).
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